XTL Biopharmaceuticals Ltd ADR Asset Resilience Ratio
XTL Biopharmaceuticals Ltd ADR asset resilience ratio. XTL Biopharmaceuticals Ltd ADR (XTLB) has an Asset Resilience Ratio of 9.03% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See XTL Biopharmaceuticals Ltd ADR liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of XTL Biopharmaceuticals Ltd ADR (2003–2024)
Asset resilience ratio of XTL Biopharmaceuticals Ltd ADR from 2003 to 2024. This chart shows how XTL Biopharmaceuticals Ltd ADR's Asset Resilience Ratio has changed over time. Read XTL Biopharmaceuticals Ltd ADR balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down XTL Biopharmaceuticals Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see XTLB current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $772.00K | 9.03% |
| Total Liquid Assets | $772.00K | 9.03% |
Asset Resilience Insights
- Limited Liquidity: XTL Biopharmaceuticals Ltd ADR maintains only 9.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
XTL Biopharmaceuticals Ltd ADR Industry Peers by Asset Resilience Ratio
Compare XTL Biopharmaceuticals Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Genmab A/S
CO:GMAB |
Biotechnology | 23.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 72.03% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
XTL Biopharmaceuticals Ltd ADR Asset Resilience Ratio by Year (2003–2024)
XTL Biopharmaceuticals Ltd ADR asset resilience ratio by year from 2003 to 2024. The table below shows the annual Asset Resilience Ratio data for XTL Biopharmaceuticals Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.03% | $772.00K | $8.55 Million | -15.91pp |
| 2023-12-31 | 24.94% | $605.00K | $2.43 Million | -13.93pp |
| 2022-12-31 | 38.87% | $1.63 Million | $4.19 Million | -8.85pp |
| 2021-12-31 | 47.72% | $3.16 Million | $6.62 Million | +10.64pp |
| 2020-12-31 | 37.08% | $2.41 Million | $6.50 Million | +5.56pp |
| 2019-12-31 | 31.52% | $2.27 Million | $7.21 Million | -25.24pp |
| 2018-12-31 | 56.76% | $4.87 Million | $8.57 Million | +14.17pp |
| 2017-12-31 | 42.59% | $2.81 Million | $6.59 Million | +28.87pp |
| 2016-12-31 | 13.72% | $414.00K | $3.02 Million | +9.01pp |
| 2015-12-31 | 4.72% | $251.00K | $5.32 Million | -11.23pp |
| 2013-12-31 | 15.95% | $1.28 Million | $8.02 Million | +1.37pp |
| 2012-12-31 | 14.58% | $1.62 Million | $11.09 Million | -19.11pp |
| 2011-12-31 | 33.69% | $1.37 Million | $4.07 Million | +5.61pp |
| 2010-12-31 | 28.07% | $1.07 Million | $3.80 Million | +26.91pp |
| 2008-12-31 | 1.17% | $40.00K | $3.43 Million | -73.87pp |
| 2007-12-31 | 75.03% | $10.60 Million | $14.13 Million | -2.84pp |
| 2006-12-31 | 77.87% | $20.95 Million | $26.90 Million | +38.31pp |
| 2004-12-31 | 39.56% | $10.14 Million | $25.62 Million | -33.18pp |
| 2003-12-31 | 72.74% | $18.08 Million | $24.85 Million | -- |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more